Home › Metastatic Cancer › Oklahoma › Oklahoma City
Metastatic Cancer clinical trials in Oklahoma City, OK
16 studies for Metastatic Cancer are looking for participants at sites in and around Oklahoma City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
RecruitingPhase 1/2
- Avenzo Therapeutics Recruiting Site, Oklahoma City
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- University of Oklahoma, Oklahoma City
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
RecruitingPhase 1
- University of Oklahoma Health Sciences Center, Oklahoma City
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RecruitingPhase 3
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecruitingPhase 1/2
- University of Oklahoma, Oklahoma City
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
RecruitingPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RecruitingPhase 1
- University of Oklahoma - Health Sciences Center, Oklahoma City
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
RecruitingPhase 1
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
RecruitingPhase 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Stephenson Cancer Center, Oklahoma City
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
RecruitingPhase 1/2
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
RecruitingObservational study
- Mercy Hospital Oklahoma City, Oklahoma City
Circulating Tumor DNA Response In Urothelial Cancer
RecruitingPhase 2
- OU Health Stephenson Cancer Center, Oklahoma City
Spine Radiosurgery for Symptomatic Metastatic Neoplasms
RecruitingPhase 2
- OU Health Stephenson Cancer Center, Oklahoma City
A Study of NX-1607 in Adults With Advanced Malignancies
RecruitingPhase 1
- University of Oklahoma, Oklahoma City
Metastatic Cancer trials in other cities
- Houston, TX104 studies
- New York City, NY93 studies
- Nashville, TN70 studies
- Boston, MA63 studies
- Los Angeles, CA57 studies
- St. Louis, MO54 studies
- Arlington, VA53 studies
- Philadelphia, PA46 studies
- Chicago, IL45 studies
- San Antonio, TX44 studies
- Washington, DC43 studies
- Dallas, TX42 studies
Other studies in Oklahoma City
- Non-Small Cell Lung Cancer28 studies
- Ovarian Cancer28 studies
- Endometrial Cancer25 studies
- Colorectal Cancer22 studies
- Prostate Cancer21 studies
- Lung Cancer19 studies
- Breast Cancer17 studies
- Cancer (all types)14 studies
- Acute Myeloid Leukemia14 studies
- Head and Neck Squamous Cell Carcinoma13 studies
- Bladder Cancer11 studies
- Pancreatic Cancer11 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.